A New Breakthrough in Stroke Recovery: Scientifically Validated Neurorestoration Technology

Real Challenges Faced by Stroke Patients

Are you or your loved ones experiencing:

Limb mobility impairment, difficulty walking, loss of fine motor skills?
Memory decline, inability to concentrate, slowed thinking?
Speech difficulties, swallowing problems, communication barriers?
Emotional lows, anxiety, depression, poor sleep quality?
Slow progress and limited results with traditional rehabilitation?
Seeking safe and effective non-pharmacological adjunctive treatment options?

COZING-C320A Brings You Hope—featuring 810nm+650nm dual-wavelength phototherapy technology based on NEST-1/NEST-2 clinical research, providing scientific support for post-stroke neurological function recovery.

Clinically Validated Treatment Efficacy

Key Research Data Support

NEST-1 Study: 120 patients, 70% good prognosis at 90 days post-treatment (vs. 51% control group)
NEST-2 Study: 660 patients, significant improvement in moderate-to-severe patients (p<0.04)
Treatment Window: Best results when initiated within 24 hours in acute phase

Quadruple Scientific Action Mechanism

Mitochondrial Energization: 810nm light penetrates skull, increases ATP production by 50-200%
Neuroprotection: Reduces inflammatory factors, inhibits apoptosis
Angiogenesis: Promotes collateral circulation establishment, improves cerebral blood flow
Neural Remodeling: Enhances synaptic plasticity, promotes functional reorganization

Personalized Treatment Protocols

Phase 1: Acute Phase (Days 1-14 post-onset)

Goal: Neuroprotection, reducing secondary damage
Parameters: 810nm primary wavelength, 10Hz, 25-50% intensity, 1-2 times daily
Focus: Full-brain coverage + enhanced contralateral lesion treatment

Phase 2: Recovery Phase (Days 15-90)

Goal: Functional recovery, neural remodeling
Parameters: Dual-wavelength synergy, 20-30Hz, 50-75% intensity
Personalized Settings:
- Motor Impairment: Focus on regions 3-4, use before physical therapy
- Cognitive Impairment: Focus on regions 1-2, use before cognitive training
- Speech Impairment: Enhanced Broca's area treatment

Phase 3: Maintenance Phase (90+ days)

Goal: Functional consolidation, relapse prevention
Parameters: 10-40Hz alternating, 50-60% intensity, 3-4 times weekly
Home Rehabilitation: Simplified operation for long-term adherence

Technical Specifications and Advantages

12-Brain-Region Precision Modulation

Zoned Treatment Design:
Frontal Regions (1-4): Motor, executive function, emotion
Parietal Regions (5-6): Sensation, spatial cognition
Temporal Regions (7-8): Memory, auditory
Occipital Regions (9-10): Visual processing
Limbic System (11-12): Emotion, autonomic function

Core Specifications

Parameter	Specification
Wavelength	810nm + 650nm Dual Wavelength
Frequency Range	1-20,000Hz Adjustable
Default Frequency	30Hz (Clinically Optimized)
Treatment Duration	0-30 Minutes Programmable
Intensity Levels	4 Levels (25%/50%/75%/100%)
Control Methods	Manual + Wireless Remote
Nasal/Ear Accessories	Includes nasal irradiation attachments
Safety Class	Laser Class 1M

Six Major Advantages

Clinically Validated: Based on NEST series research protocols
Precise Targeting: 12 independent zone control
Dual-Wavelength Synergy: Deep treatment + surface repair
Safe & Non-Invasive: Pain-free, no side effects
Easy Operation: Suitable for home and professional settings
Personalized Protocols: Customized for different phases

Standard Operating Procedure

Assessment Phase

Professional evaluation (NIHSS scoring, imaging examination)
Develop personalized protocol
Identify key treatment areas

Treatment Phase

Device preparation and cleaning
Patient comfortable positioning
Set treatment parameters
Initiate treatment program
Real-time response monitoring

Optimization Phase

Weekly functional assessment
Monthly protocol adjustment
Long-term efficacy tracking

Safe Usage Guidelines

Indications

Ischemic stroke rehabilitation
Hemorrhagic stroke recovery
TIA (Transient Ischemic Attack)
Post-stroke complication management

Contraindications

Active intracranial hemorrhage
Severe intracranial hypertension
Photosensitive epilepsy
Intracranial malignant tumors

Safety Principles

Professional guidance required for initial use
Start with low intensity
Close response observation
Regular assessment and adjustment

Frequently Asked Questions

Q1: When is the best time to start treatment?

A: Best within 24 hours in acute phase, but still effective when started in subacute and chronic phases.